Sino Biopharm CEO Tse says AI, internationalization anchor counter-cyclical growth strategy

PUBT · 1d ago
Sino Biopharm CEO Tse says AI, internationalization anchor counter-cyclical growth strategy
  • Sino Biopharmaceutical CEO Eric Tse told the Yabuli Forum on Sept. 5 it is pursuing counter-cyclical growth through AI investment and international expansion.
  • SBP has invested CNY 600 million over three years to deploy AI across R&D, manufacturing, and management to lift drug development efficiency.
  • AI-assisted development supports 25 early-stage pipelines and 37 clinical-stage programs; COPD drug TQC3721 was licensed to AstraZeneca for USD 1.9 billion.
  • Licensing deals with Sanofi and AstraZeneca total about USD 3.5 billion this year; SBP also in-licensed bepirovirsen from GSK.
  • Tse said internationalization aims to diversify revenue exposure by aligning R&D with demand across China, the US, Europe, and emerging markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 06, 2026, and is solely responsible for the information contained therein.